Does Hemoabdomen Mean Cancer in Dogs?
What the Latest Research Actually Shows
By Steve Mehler, DVM, DACVS
Revisiting the double two-thirds rule, splenic hemangiosarcoma, and the importance of evidence-based decision-making in dogs with spontaneous abdominal hemorrhage.
A dog presents to an emergency veterinary hospital with weakness, pale mucous membranes, abdominal distension, and signs of circulatory shock.
Focused abdominal ultrasonography identifies free abdominal fluid consistent with hemorrhage. Further examination reveals a splenic mass.
The clinical concern is immediate: Is this hemangiosarcoma?
For decades, veterinarians have relied on estimates suggesting that most dogs presenting with spontaneous hemoabdomen from a ruptured splenic mass have cancer.
Those concerns are justified. Splenic hemangiosarcoma is a common and aggressive malignancy, and spontaneous rupture can cause life-threatening hemorrhage.
However, the probability of cancer is not the same as a confirmed cancer diagnosis.
Recent research provides a more nuanced picture—and raises important questions about how veterinarians communicate risk to owners facing difficult emergency decisions.
Understanding Hemoabdomen
Hemoabdomen, also called hemoperitoneum, refers to the accumulation of blood within the abdominal cavity.
It is a clinical finding, not a specific disease.
In dogs, abdominal hemorrhage can occur because of trauma, rupture of an intra-abdominal mass, vascular injury, coagulation disorders, or other less common conditions.
Spontaneous or nontraumatic hemoabdomen is particularly concerning because an underlying abdominal mass is a common cause.
The spleen is frequently implicated, and splenic hemangiosarcoma remains one of the most important differential diagnoses.
But benign splenic lesions can also rupture and bleed.
The challenge is determining the cause quickly enough to guide treatment while recognizing the limitations of the available diagnostic information.
The Double Two-Thirds Rule: Where Did It Come From?
Veterinary education has long referenced the double two-thirds rule when discussing canine splenic masses.
In its traditional form, the rule suggests that approximately two-thirds of splenic masses are malignant and that approximately two-thirds of malignant masses are hemangiosarcoma.
This framework was intended as a general estimate.
However, the probability of malignancy depends on the population being evaluated.
An incidentally discovered splenic nodule in a stable dog is not the same clinical scenario as a ruptured splenic tumor causing significant hemorrhage.
When those populations are combined or discussed interchangeably, risk estimates become misleading.
That distinction is central to understanding the modern literature.
The 2023 Systematic Review: 73% Malignancy
A systematic review by Schick and Grimes, published in the January 2023 issue of the Journal of the American Veterinary Medical Association, examined the validity of the double two-thirds rule specifically in dogs with nontraumatic hemoperitoneum caused by a ruptured splenic mass.
The researchers reviewed 14 studies encompassing 1,150 dogs.
They found:
Diagnosis | Number of dogs | Percentage |
Malignant splenic lesion | 840 | 73.0% |
Benign splenic lesion | 310 | 27.0% |
Hemangiosarcoma | 733 | 63.7% of all dogs |
Hemangiosarcoma accounted for 87.3% of malignant lesions.
The distinction between that percentage and the overall prevalence of hemangiosarcoma is important.
Saying that 87.3% of malignant lesions were hemangiosarcoma does not mean that 87.3% of dogs had hemangiosarcoma.
In this review, approximately 63.7% of all included dogs had hemangiosarcoma.
The authors also identified important limitations in the underlying research. Most included studies were retrospective, the overall level of evidence was low, and the risk of bias was high.
Therefore, although the review provides valuable information, its pooled results should not be interpreted as an exact probability for every patient.
The 2025 Prospective Study: More Benign Disease Than Previously Reported
A more recent investigation provides particularly relevant data.
In 2025, Ruffoni and colleagues published a prospective observational study involving 345 dogs with spontaneous hemoperitoneum caused by ruptured splenic tumors.
The study collected cases through a multicenter research program and evaluated histopathologic diagnoses following splenectomy.
The results were:
Diagnosis | Number of dogs | Percentage |
Hemangiosarcoma | 194 | 56.2% |
Other malignant tumors | 28 | 8.1% |
Benign lesions | 123 | 35.7% |
Total | 345 | 100% |
Overall, 64.3% of dogs had malignant tumors, while 35.7% had benign lesions.
This means that more than one-third of the dogs in the study had a benign splenic diagnosis despite presenting with significant spontaneous abdominal hemorrhage associated with a ruptured splenic tumor.
The most common benign finding was nodular hyperplasia.
The study also found no statistically significant difference in age or body weight when comparing dogs with benign lesions, hemangiosarcoma, and other malignancies.
That observation is particularly relevant when counseling owners of older or larger dogs.
Age and breed remain important clinical considerations, but neither should be treated as a substitute for establishing a diagnosis.
Important limitations
The 2025 study is a valuable contribution because the cohort was prospectively enrolled across multiple hospitals.
However, it was not a survey of every dog presenting with hemoabdomen.
The study focused on dogs undergoing splenectomy for ruptured splenic tumors. Its enrollment criteria included a body weight greater than 5 kg and excluded dogs with radiographically evident pulmonary metastasis and certain concurrent malignancies.
Those criteria affect which patients were represented.
The findings therefore apply most directly to dogs meeting similar clinical and treatment criteria.
They should not be generalized automatically to all dogs presenting to an emergency hospital with abdominal hemorrhage.
A Separate Splenectomy Study Reaches Similar Findings
Additional evidence supports the need to reconsider overly rigid assumptions.
A study published in PLOS ONE evaluated 182 dogs undergoing splenectomy for splenic masses or nodules.
Among the 91 dogs with concurrent hemoperitoneum, 60.4% had malignant splenic lesions.
That result is reasonably consistent with the approximately 64% malignancy rate reported in the 2025 prospective cohort.
It also illustrates another important principle: malignancy rates in dogs with bleeding splenic lesions differ substantially from those in dogs whose splenic abnormalities are discovered incidentally.
The presenting condition matters.
What About Dogs With Spontaneous Hemoabdomen From Any Cause?
This is a separate—and more difficult—question.
When a dog presents with spontaneous hemoabdomen, the bleeding source may not initially be known.
Although the spleen is a common source, hemorrhage can also originate from the liver, kidney, adrenal gland, other abdominal tissues, or non-neoplastic conditions.
A 2021 multicenter study by Wright and colleagues evaluated 168 dogs receiving surgical or medical management for acute spontaneous hemoperitoneum.
The authors reported malignancy in 55.3% of patients who received a definitive diagnosis.
However, not all enrolled dogs received a definitive diagnosis, particularly among medically managed patients.
The study also excluded patients euthanized or discharged during the first 12 hours.
Consequently, the reported malignancy rate does not represent a reliable universal probability for every dog that presents with spontaneous hemoabdomen.
This is a critical epidemiologic distinction.
A malignancy percentage derived from surgically treated dogs with confirmed splenic masses cannot be applied to all dogs with hemorrhagic abdominal effusion.
Why the Source of Hemorrhage Changes the Discussion
Consider dogs with spontaneous hemoperitoneum caused by ruptured liver masses.
A multicenter retrospective study examined 200 dogs undergoing liver lobectomy for hemorrhage originating from a liver mass.
The histopathologic diagnoses included:
36% well-differentiated hepatocellular carcinoma
27.5% benign lesions
25.5% hemangiosarcoma
11% other malignant tumors
Overall, 72.5% had malignant diagnoses.
Yet the prognosis was not uniformly poor.
Dogs with well-differentiated hepatocellular carcinoma had substantially more favorable reported survival after surgery than those with hemangiosarcoma.
This distinction underscores an often-overlooked point:
Malignancy does not always imply the same biological behavior, treatment options, or expected outcome.
The organ of origin and specific histopathologic diagnosis may be just as important as the broad distinction between benign and malignant disease.
Can Ultrasound Tell Us Whether a Mass Is Malignant?
Ultrasonography is essential in the evaluation of suspected hemoabdomen.
It can help identify free abdominal fluid, suggest a likely source of hemorrhage, identify abdominal masses, and provide information useful for treatment planning.
However, ultrasound findings are not equivalent to histopathology.
The appearance of a splenic mass cannot reliably establish whether it is benign or malignant in an individual patient.
Similarly, the presence of multiple abdominal lesions does not necessarily prove malignancy.
Computed tomography may provide additional anatomical and staging information, but it has its own limitations.
In a small retrospective study of 26 dogs with nontraumatic hemoperitoneum, investigators found that evaluated CT imaging characteristics did not reliably differentiate benign and malignant lesions.
When feasible, imaging should be used to inform clinical planning and staging—not to replace definitive tissue diagnosis.
Does Age or Breed Determine the Diagnosis?
Certain dog breeds have a recognized predisposition to splenic hemangiosarcoma, and older dogs are frequently represented in clinical studies of splenic masses.
These associations are clinically relevant.
However, a predisposition is not a diagnosis.
The 2025 prospective study did not identify statistically significant differences in age or body weight across its diagnostic groups.
That finding does not establish that breed or age never influence risk. Rather, it cautions against treating signalment alone as conclusive evidence of hemangiosarcoma in a dog already presenting with a ruptured splenic tumor.
A ten-year-old large-breed dog with spontaneous hemoabdomen may certainly have hemangiosarcoma.
But that same dog may also have a benign splenic lesion.
Both possibilities deserve consideration.
The Clinical Decision: More Than a Percentage
Hemoabdomen is a potentially life-threatening emergency regardless of whether the underlying cause is benign or malignant.
Immediate priorities generally include evaluating perfusion and hemodynamic stability, assessing the severity and progression of hemorrhage, and initiating appropriate resuscitation.
Depending on the patient, this may involve vascular access, blood work, serial hematocrit and total solids measurements, focused ultrasonography, blood product support, and further diagnostic imaging when clinically appropriate.
The decision to pursue surgery depends on multiple factors, including:
Hemodynamic status and response to stabilization
Suspected organ and source of hemorrhage
Evidence of metastatic or concurrent disease
Anesthetic and surgical risks
The availability of appropriate surgical and critical care resources
Owner preferences, financial considerations, and goals of care
The probability of malignancy is an important part of this discussion, but it is not the only consideration.
The presence of a benign lesion does not make active hemorrhage harmless. Conversely, the possibility of malignancy does not, by itself, establish that treatment is inappropriate.
Histopathology is often required to distinguish a benign splenic lesion from hemangiosarcoma or another malignancy.
When histopathology is unavailable, clinicians should be careful to distinguish a suspected diagnosis from a confirmed one.
What Should We Tell Pet Parents?
A more useful approach to client communication is to explain both the seriousness of the condition and the uncertainty of the underlying diagnosis.
For a dog with a confirmed ruptured splenic tumor, the current literature supports a substantial malignancy risk.
A reasonable way to frame the 2025 prospective findings is that approximately two-thirds of such dogs had malignant disease, while approximately one-third had benign disease.
That estimate is not a guarantee for an individual patient, and the study's enrollment criteria must be kept in mind.
The essential message should be balanced:
The hemorrhage is serious. Hemangiosarcoma is a significant concern. But benign disease remains a meaningful possibility.
That is a more accurate foundation for discussing diagnostic testing, surgery, prognosis, and available alternatives than stating or implying that cancer is already established.
The Bottom Line
The diagnosis of hemoabdomen should never be considered synonymous with hemangiosarcoma.
A 2023 systematic review found malignant lesions in 73% of dogs with nontraumatic hemoperitoneum caused by ruptured splenic masses.
A 2025 prospective observational study found malignancy in 64.3% and benign disease in 35.7% of dogs undergoing splenectomy for ruptured splenic tumors.
These studies demonstrate why clinical context and study population matter.
The probability of malignancy changes depending on the bleeding source, patient selection, and whether a definitive diagnosis is obtained.
For clinicians, the goal should not be to replace one simplistic rule with another.
It should be to combine the best available evidence with patient-specific findings, sound clinical judgment, and clear communication.
The presence of blood in the abdomen is a clinical emergency. It is not, by itself, a diagnosis of cancer.
And when owners are facing decisions about potentially lifesaving surgery or euthanasia, that distinction matters.
References
Schick AR, Grimes JA. Evaluation of the validity of the double two-thirds rule for diagnosing hemangiosarcoma in dogs with nontraumatic hemoperitoneum due to a ruptured splenic mass: a systematic review. JAVMA. 2023;261(1):69–73. DOI: 10.2460/javma.22.08.0389.
Ruffoni E, et al. A prospective observational study of 345 canines with ruptured splenic tumors suggests benign lesions are more common than previously reported. JAVMA. 2025;263(8):985–990. DOI: 10.2460/javma.25.01.0044.
Incidence of splenic malignancy and hemangiosarcoma in dogs undergoing splenectomy surgery at a surgical specialty clinic: 182 cases (2017–2021). PLOS ONE. PubMed.
Wright et al. Outcomes and blood product use in 89 surgically managed and 79 medically managed cases of acute spontaneous hemoperitoneum in the dog. Frontiers in Veterinary Science. 2021. DOI: 10.3389/fvets.2021.736329.
Reist AM, Reagan JK, Fujita SK, Walny AM. Histopathologic findings and survival outcomes of dogs undergoing liver lobectomy as treatment for spontaneous hemoabdomen secondary to a ruptured liver mass: retrospective analysis of 200 cases. JAVMA. 2023;261(2):237–245. DOI: 10.2460/javma.22.03.0130.
Parry ME, et al. Retrospective evaluation of the diagnostic utility of computed tomography in dogs with nontraumatic hemoperitoneum: 26 cases (2015–2020). Journal of Veterinary Emergency and Critical Care. 2023. DOI: 10.1111/vec.13310.
Comments